Solid Biosciences LLC (NASDAQ:SLDB) — Market Cap & Net Worth
Market Cap & Net Worth: Solid Biosciences LLC (SLDB)
Solid Biosciences LLC (NASDAQ:SLDB) has a market capitalization of $935.00 Million ($935.00 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9212 globally and #2587 in its home market, demonstrating a -12.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Solid Biosciences LLC's stock price $8.72 by its total outstanding shares 107225238 (107.23 Million). Also see SLDB current and non-current assets for a full breakdown of the balance sheet.
Solid Biosciences LLC Market Cap History: 2018 to 2026
Solid Biosciences LLC's market capitalization history from 2018 to 2026. Data shows change from $43.10 Billion to $935.00 Million (-34.53% CAGR). Also see Solid Biosciences LLC cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Solid Biosciences LLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.04% | #263 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #977 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.05% | #154 of 263 |
Weight: Solid Biosciences LLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Solid Biosciences LLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Solid Biosciences LLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Solid Biosciences LLC (SLDB) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
71.27x
Solid Biosciences LLC's market cap is 71.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $12.19 Billion | $3.33 Million | -$88.29 Million | 3655.63x | N/A |
| 2021 | $2.81 Billion | $13.62 Million | -$72.19 Million | 206.66x | N/A |
| 2022 | $576.87 Million | $8.09 Million | -$85.98 Million | 71.27x | N/A |
Competitor Companies of SLDB by Market Capitalization
Companies near Solid Biosciences LLC in the global market cap rankings as of September 18, 2026. Review Solid Biosciences LLC (SLDB) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Solid Biosciences LLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Solid Biosciences LLC Historical Marketcap From 2018 to 2026
Between 2018 and today, Solid Biosciences LLC's market cap moved from $43.10 Billion to $ 935.00 Million, with a yearly change of -34.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $935.00 Million | +54.61% |
| 2025 | $604.75 Million | +41.00% |
| 2024 | $428.90 Million | -34.85% |
| 2023 | $658.36 Million | +14.13% |
| 2022 | $576.87 Million | -79.50% |
| 2021 | $2.81 Billion | -76.91% |
| 2020 | $12.19 Billion | +70.34% |
| 2019 | $7.16 Billion | -83.40% |
| 2018 | $43.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Solid Biosciences LLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $935.00 Million USD |
| MoneyControl | $935.00 Million USD |
| MarketWatch | $935.00 Million USD |
| marketcap.company | $935.00 Million USD |
| Reuters | $935.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachyca… Read more